In August 2021, the FDA approved Roche’s VENTANA MMR RxDx Panel to identify dMMR solid tumor patients eligible for anti-PD-1 immunotherapy.
Growing Prevalence of Chronic Diseases
As per the Joint Research Commission’s report of European Commission released in July 2020, it was estimated that in 2020 about 2.7 million (excluding non-melanoma cancer) new cancer cases would be diagnosed in the European Union, and breast cancer will be the most prevalent form of cancer with about 355,000 new cases in 2020.
Growing Demand for Personalized Medicine
Download Free Sample Report

Market Segmentation
Global Immunohistochemistry market can be segmented on the basis of product, application, end user, and by region. Based on product, the market can be segmented into antibodies, equipment, reagents, and kits. On the basis of application, the market can be segmented into diagnostics, drug testing, and forensic applications. Based on end user, the market can be further divided into hospitals & diagnostic laboratories, research institutes, and others. On the basis of region, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global immunohistochemistry market on account of the growing prevalence of chronic diseases in the country.
Recent Development
In June 2022, Roche launched HPV self-sampling solution and expanding cervical cancer screening options.
In February 2022, Moderna and Thermo Fisher Scientific announced long term strategic collaboration for manufacturing of Spikevax vaccine in the U.S. for diagnosis of COVID-19 and other investigational mRNA medicines in this pipeline.
In February 2022, new genetic analyzer brought advanced capabilities to sanger sequencing and fragment analysis which is called as capillary electrophoresis and it enables sanger sequencing and fragment analysis, which is essential for improving clinical research and advancing scientific discovery.
Market Players
Thermo Fisher Scientific Inc.
Attribute | Details |
Base Year | 2022 |
Historic Data | 2018 – 2021 |
Estimated Year | 2023 |
Forecast Period | 2024 – 2028 |
Quantitative Units | Revenue in USD Million, and CAGR for 2018-2022 and 2023-2028 |
Report Coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered | By Product By Application By End User By Region |
Regional scope | North America, Europe, Asia Pacific, South America, Middle East & Africa |
Country scope | United States, Canada, Mexico, France, Germany, United Kingdom, Italy, Spain, China, India, Japan, South Korea, Australia, Brazil, Argentina, Colombia, South Africa, Saudi Arabia, UAE |
Key companies profiled | Thermo Fisher Scientific Inc., F.Hoffmann-La Roche Ltd., Merck KGaA., Danaher Corporation., Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology Inc., Bio SB., Agilent Technologies, Inc. |
Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |